{"id":50585,"date":"2022-11-08T02:02:04","date_gmt":"2022-11-08T01:02:04","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/10-studies-on-orelabrutinib-selected-at-the-upcoming-64th-annual-meeting-of-ash\/"},"modified":"2022-11-08T02:02:04","modified_gmt":"2022-11-08T01:02:04","slug":"10-studies-on-orelabrutinib-selected-at-the-upcoming-64th-annual-meeting-of-ash","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/10-studies-on-orelabrutinib-selected-at-the-upcoming-64th-annual-meeting-of-ash\/","title":{"rendered":"10 Studies on Orelabrutinib Selected at the Upcoming 64th Annual Meeting of ASH"},"content":{"rendered":"
\n

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that 10 studies on the BTK inhibitor orelabrutinib developed by InnoCare were selected at the 64th American Society of Hematology (ASH) Annual Meeting on December 10-13, 2022, which will be held online and offline in New Orleans, United States.\n<\/p>\n

\nOral Presentation<\/b>\n<\/p>\n

\nTitle: Orelabrutinib, Rituximab, and High-Dose Methotrexate (HD-MTX) in Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis on Efficacy, Safety, and Biomarker\n<\/p>\n

\nAbstract Number: 558\n<\/p>\n

\nSession Name: 627. Aggressive Lymphomas: Clinical and Epidemiological: Real World Evidence for Management of CNS Lymphoma and Post CAR T-cell relapse for aggressive B-cell NHL\n<\/p>\n

\nPresentation Time: 1:15 PM, Dec. 11, 2022 (Sunday)\n<\/p>\n

\nFirst Author: Shihua Zhao\n<\/p>\n

\nCorresponding Author: Wenrong Huang\n<\/p>\n

\nPoster Presentation 1<\/b>\n<\/p>\n

\nTitle: A Multicenter, Single-Arm, Prospective Phase \u2161 Study of Orelabrutinib Combined with High-Dose Methotrexate and Rituximab Sequential Autologous Hematopoietic Stem Cell Transplantation in Newly-Diagnosed Primary Central Nervous System Lymphoma\n<\/p>\n

\nAbstract Number: 1624\n<\/p>\n

\nSession Name: 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I\n<\/p>\n

\nPresentation Time: 5:30-7:30 PM, Dec. 10, 2022 (Saturday)\n<\/p>\n

\nFirst Author: Ji Ma\n<\/p>\n

\nPoster Presentation 2<\/b>\n<\/p>\n

\nTitle: Efficacy and Safety of Lenalidomide, Anti-PD-1 Antibody Combined with Orelabrutinib or Rituximab in the Treatment of Patients with Relapsed\/Refractory Diffuse Large B-Cell Lymphoma\n<\/p>\n

\nAbstract Number: 1636\n<\/p>\n

\nSession Name: 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I\n<\/p>\n

\nPresentation Time: 5:30-7:30 PM, Dec. 10, 2022 (Saturday)\n<\/p>\n

\nFirst Author: Yuqing Miao\n<\/p>\n

\nCorresponding Author: Hao Xu\n<\/p>\n

\nPoster Presentation 3<\/b>\n<\/p>\n

\nTitle: Preliminary Result of Phase 1 Trial of Orelabrutinib in Combination with Rituximab, Methotrexate, and Dexamethasone in Patients with Newly Diagnosed Primary CNS Lymphoma Implementing Bayesian Design for Dose-Seeking\n<\/p>\n

\nAbstract Number: 2951\n<\/p>\n

\nSession Name: 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster II\n<\/p>\n

\nPresentation Time: 6:00-8:00 PM, Dec. 11, 2022 (Sunday)\n<\/p>\n

\nFirst Author: Yan Yuan\n<\/p>\n

\nCorresponding Author: Tong Chen\n<\/p>\n

\nPoster Presentation 4<\/b>\n<\/p>\n

\nTitle: Thiotepa, Orelabrutinib, and Methotrexate Combined with or without the Rituximab Regimens in the Treatment of Patients with Central Nervous System Lymphoma\n<\/p>\n

\nAbstract Number: 4291\n<\/p>\n

\nSession Name: 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster \u2162\n<\/p>\n

\nPresentation Time: 6:00-8:00 PM, Dec. 12, 2022 (Monday)\n<\/p>\n

\nFirst Author: Ruolan Zeng\n<\/p>\n

\nCorresponding Author: Hui Zhou\n<\/p>\n

\nPoster Presentation 5<\/b>\n<\/p>\n

\nTitle: Orelabrutinib in Combination with Rituximab and chemotherapy for Newly Diagnosed Aggressive B-Cell Lymphoma: A Multicenter, Single-Arm, Prospective Study\n<\/p>\n

\nAbstract Number: 4295\n<\/p>\n

\nSession Name: 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster \u2162\n<\/p>\n

\nPresentation Time: 6:00-8:00 PM, Dec. 12, 2022 (Monday)\n<\/p>\n

\nFirst Author: Xiangxiang Zhou\n<\/p>\n

\nCorresponding Author: Xin Wang\n<\/p>\n

\nOnline Abstract 1<\/b>\n<\/p>\n

\nTitle: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of Orelabrutinib Plus R-CHOP Versus Placebo Plus R-CHOP in Treatment-Naive Patients with Mcd Subtype Diffuse Large B-Cell Lymphoma\n<\/p>\n

\nAbstract Number: 5525\n<\/p>\n

\nFirst Author: Weili Zhao\n<\/p>\n

\nCorresponding Author: Pengpeng Xu\n<\/p>\n

\nOnline Abstract 2<\/b>\n<\/p>\n

\nTitle: A Phase I\/II Study of Orelabrutinib Combined with Anti-Programmed Cell Death Protein-1 Antibody and Fotemustine for Patients with Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL)\n<\/p>\n

\nAbstract Number: 5508\n<\/p>\n

\nFirst Author: Xudong Zhang\n<\/p>\n

\nCorresponding Author: Mingzhi Zhang\n<\/p>\n

\nOnline Abstract 3<\/b>\n<\/p>\n

\nTitle: Preliminary Outcomes of Orelabrutinib Plus RCHOP in Treatment-Na\u00efve Patients with Double-Expression Diffuse Large B Cell Lymphoma\n<\/p>\n

\nAbstract Number: 5521\n<\/p>\n

\nFirst Author: Yang Yang\n<\/p>\n

\nCorresponding Author: Zhen Cai\n<\/p>\n

\nOnline Abstract 4<\/b>\n<\/p>\n

\nTitle: Orelabrutinib and Venetoclax Show Synergistic Lethality in Double-Hit Lymphoma By Interfering with the Crosstalk between the PI3K\/AKT and p38\/MAPK Signaling\n<\/p>\n

\nAbstract Number: 5248\n<\/p>\n

\nFirst Author: Mengya Zhong\n<\/p>\n

\nCorresponding Author: Bing Xu\n<\/p>\n

\nAbout Orelabrutinib<\/b>\n<\/p>\n

\nOrelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.\n<\/p>\n

\nOn Dec. 25 2020, orelabrutinib received conditional approval from the China National Medical Products Administration (NMPA) in two indications: the treatment of patients with relapsed\/refractory chronic lymphocytic leukemia (CLL) \/small lymphocytic lymphoma (SLL), and the treatment of patients with relapsed\/refractory mantle cell lymphoma (MCL). At the end of 2021, orelabrutinib was included into National Reimbursement Drug list to benefit more lymphoma patients.\n<\/p>\n

\nThe supplemental New Drug Applications of orelabrutinib for the treatment of R\/R WM and R\/R Marginal Zone Lymphoma were accepted in China.\n<\/p>\n

\nIn addition to the approved indications, multi-center, multi-indication clinical trials are underway in the US and China with orelabrutinib as monotherapy or in combination therapies, such as first line treatment of MCD subtype of diffuse large B-cell lymphoma (DLBCL).\n<\/p>\n

\nOrelabrutinib was granted as Breakthrough Therapy Designation for the treatment of r\/r MCL by U.S. Food and Drug Administration (FDA).\n<\/p>\n

\nIn addition, orelabrutinib is also being evaluated in global phase II studies for the treatment of Multiple Sclerosis (MS), and clinical trials for the treatment of SLE, Primary Immune Thrombocytopenia (ITP) and Neuromyelitis Optica Spectrum Disorder (NMOSD) in China.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia
\n
<\/b>Chunhua Lu
\n
86-10-66609879
\n
chunhua.lu@innocarepharma.com<\/a><\/p>\n

Investor Relations
\n
\n<\/b>
86-10-66609999
\n
ir@innocarepharma.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that 10 studies on the BTK inhibitor orelabrutinib developed by InnoCare were selected at the 64th American Society of Hematology (ASH) Annual Meeting on December 10-13, 2022, which will be held online and … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50585","6":"format-standard","7":"category-industry"},"yoast_head":"\n10 Studies on Orelabrutinib Selected at the Upcoming 64th Annual Meeting of ASH - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/10-studies-on-orelabrutinib-selected-at-the-upcoming-64th-annual-meeting-of-ash\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"10 Studies on Orelabrutinib Selected at the Upcoming 64th Annual Meeting of ASH - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that 10 studies on the BTK inhibitor orelabrutinib developed by InnoCare were selected at the 64th American Society of Hematology (ASH) Annual Meeting on December 10-13, 2022, which will be held online and ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/10-studies-on-orelabrutinib-selected-at-the-upcoming-64th-annual-meeting-of-ash\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-08T01:02:04+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/10-studies-on-orelabrutinib-selected-at-the-upcoming-64th-annual-meeting-of-ash\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/10-studies-on-orelabrutinib-selected-at-the-upcoming-64th-annual-meeting-of-ash\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"10 Studies on Orelabrutinib Selected at the Upcoming 64th Annual Meeting of ASH\",\"datePublished\":\"2022-11-08T01:02:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/10-studies-on-orelabrutinib-selected-at-the-upcoming-64th-annual-meeting-of-ash\\\/\"},\"wordCount\":759,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/10-studies-on-orelabrutinib-selected-at-the-upcoming-64th-annual-meeting-of-ash\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/10-studies-on-orelabrutinib-selected-at-the-upcoming-64th-annual-meeting-of-ash\\\/\",\"name\":\"10 Studies on Orelabrutinib Selected at the Upcoming 64th Annual Meeting of ASH - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-11-08T01:02:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/10-studies-on-orelabrutinib-selected-at-the-upcoming-64th-annual-meeting-of-ash\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/10-studies-on-orelabrutinib-selected-at-the-upcoming-64th-annual-meeting-of-ash\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/10-studies-on-orelabrutinib-selected-at-the-upcoming-64th-annual-meeting-of-ash\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"10 Studies on Orelabrutinib Selected at the Upcoming 64th Annual Meeting of ASH\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"10 Studies on Orelabrutinib Selected at the Upcoming 64th Annual Meeting of ASH - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/10-studies-on-orelabrutinib-selected-at-the-upcoming-64th-annual-meeting-of-ash\/","og_locale":"en_US","og_type":"article","og_title":"10 Studies on Orelabrutinib Selected at the Upcoming 64th Annual Meeting of ASH - Pharma Trend","og_description":"BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that 10 studies on the BTK inhibitor orelabrutinib developed by InnoCare were selected at the 64th American Society of Hematology (ASH) Annual Meeting on December 10-13, 2022, which will be held online and ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/10-studies-on-orelabrutinib-selected-at-the-upcoming-64th-annual-meeting-of-ash\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-08T01:02:04+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/10-studies-on-orelabrutinib-selected-at-the-upcoming-64th-annual-meeting-of-ash\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/10-studies-on-orelabrutinib-selected-at-the-upcoming-64th-annual-meeting-of-ash\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"10 Studies on Orelabrutinib Selected at the Upcoming 64th Annual Meeting of ASH","datePublished":"2022-11-08T01:02:04+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/10-studies-on-orelabrutinib-selected-at-the-upcoming-64th-annual-meeting-of-ash\/"},"wordCount":759,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/10-studies-on-orelabrutinib-selected-at-the-upcoming-64th-annual-meeting-of-ash\/","url":"https:\/\/pharma-trend.com\/en\/10-studies-on-orelabrutinib-selected-at-the-upcoming-64th-annual-meeting-of-ash\/","name":"10 Studies on Orelabrutinib Selected at the Upcoming 64th Annual Meeting of ASH - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-11-08T01:02:04+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/10-studies-on-orelabrutinib-selected-at-the-upcoming-64th-annual-meeting-of-ash\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/10-studies-on-orelabrutinib-selected-at-the-upcoming-64th-annual-meeting-of-ash\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/10-studies-on-orelabrutinib-selected-at-the-upcoming-64th-annual-meeting-of-ash\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"10 Studies on Orelabrutinib Selected at the Upcoming 64th Annual Meeting of ASH"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50585","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50585"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50585\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50585"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50585"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}